Pipeline Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update BioPharma DiveImmunovant shares climbed on results an analyst deemed compelling in tough-to-treat arthritis.Immunology & InflammationRead full story pharminent May 20, 2026 (Last updated: May 20, 2026) BioPharma Dive Immunovant shares climbed on results an analyst deemed compelling in tough-to-treat arthritis. Immunology & Inflammation Read full story Post navigation Previous: Pazdur declines to announce candidacy for vacated FDA commissioner roleNext: Remepy’s hybrid Parkinson’s therapy poised for phase 3 Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026 Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
